Invitro pharmacodynamicstudyof ceftobiprole,vancomycin,linezolid and daptomycin against staphylococcal bloodstream infections  

作　　者：李玲琴 LI Lingqin(State Key Lab,Infect Dis Diag&Treat,1st Affil Hosp,Zhejiang Univ Med Sch,Hangzhou 310003)

机构地区：[1]State Key Lab,Infect Dis Diag&Treat,1st Affil Hosp,Zhejiang Univ Med Sch,Hangzhou 310003

出　　处：《China Medical Abstracts(Internal Medicine)》2024年第2期83-84,共2页中国医学文摘（内科学分册（英文版）

摘　　要：Objective To evaluate the antibacterial efficacy of ceftobiprole,vancomycin,linezolid,and daptomycin against Staphylococcus aureus(SAU)and coagulasenegative Staphylococcus(CNS)bloodstream infections,which can provide a reference for clinical medication.Methods A total of 1777 strains of staphylococci were isolated from blood culture of 51 hospitals within the Blood Bacterial Resistant Investigation Collaborative System(BRICS)from January to December in 2021.The dilution method was used to assess the minimum inhibitoryyconcentrations(MIC)of ceftobiprole,vancomycin,linezolid and daptomycin on staphylococci.Additionally,the probability of target attainment(PTA)and cumulative fraction of response(CFR)of these medications in varied dosage regimens were predicted using Monte Carlo simulation.Results Ceftobiprole demonstrated significant antibacterial activity againstmethicillinresistant Staphylococcus aureus(MRSA),the MICso and MICoo were 0.500 and 1.000 mg/L,respectively,and the MIC range was≤0.060 to 4.000 mg/L.Meanwhile,the ceftobiprole-resistance rate of SAU was 0.1%(1/1073),but the resistance rate of CNS was 7.7%(54/704).

关 键 词：dosage Blood INFECTIONS 

分 类 号：R96[医药卫生—药理学]